Greenwich LifeSciences (GLSI) Cash from Operations (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Cash from Operations of 3174657.0 for Q4 2025, down 18.85% on a QoQ basis from 2671239.0 in Q3 2025, and down 71.4% year-over-year from 11099694.66 in Q4 2024.
Greenwich LifeSciences (GLSI) Cash from Operations (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Cash from Operations history runs 6 years deep, the most recent figure standing at 3174657.0 for Q4 2025.
- Quarterly Cash from Operations fell 71.4% year-over-year to 3174657.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 9913453.0 (down 36.43% YoY) and the FY2025 annual result came in at 9913453.0, down 36.43% from the prior year.
- Cash from Operations was 3174657.0 for Q4 2025 at Greenwich LifeSciences, down from 2671239.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 528270.0 in Q1 2021 and bottomed at 3174657.0 in Q4 2025.
- A 5-year average of 1707508.65 and a median of 1817538.5 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 268.65% — and 2023, when it grew 20.06%.
- Greenwich LifeSciences' Cash from Operations stood at 2264320.0 in 2021, then climbed by 4.16% to 2170061.0 in 2022, then climbed by 0.73% to 2154195.0 in 2023, then rose by 14.02% to 1852206.0 in 2024, then tumbled by 71.4% to 3174657.0 in 2025.
- Business Quant data shows GLSI's Cash from Operations at 3174657.0 in Q4 2025, 2671239.0 in Q3 2025, and 2233103.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | -3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.17 Mn |
| Dec 31, 2025 | -3.17 Mn |
| Sep 30, 2025 | -2.67 Mn |
| Sep 30, 2025 | -2.67 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.78 Mn |
| Mar 31, 2024 | -1.78 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |